Oxamniquine pharmacokinetics in hepatosplenic schistosomiasis in the Sudan.
Oxamniquine pharmacokinetics were determined in five normal Sudanese subjects and nine Sudanese patients with advanced hepatosplenic schistosomiasis, given 1 g as a single oral dose. There were no significant differences in oxamniquine mean area under the plasma concentration time curve (AUC), plasma half life (T1/2), or time to reach peak concentration (Tmax). However, patients had a 19% lower mean AUC, a 36% higher T1/2, and a 23% increase in Tmax. The peak concentration (Cmax) was 36% lower in patients (P = 0.04). There was no correlation between disease severity and oxamniquine pharmacokinetic values. A significant correlation between oxamniquine AUC and T1/2 suggests that its elimination may be non-linear. The higher dosage requirements for oxamniquine in the Sudan are unlikely to be due to lower plasma concentrations amongst the Sudanese.
D000328:Adult; D005260:Female; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008109:Liver Diseases, Parasitic / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009600:Nitroquinolines / Q000378:metabolism*; D010073:Oxamniquine / Q000378:metabolism* / Q000627:therapeutic use; D012044:Regression Analysis; D012555:Schistosomiasis mansoni / Q000188:drug therapy / Q000378:metabolism*; D013158:Splenic Diseases / Q000188:drug therapy / Q000378:metabolism*; D013397:Sudan
D009600:Nitroquinolines; D010073:Oxamniquine